Efficacy of bismuth-based quadruple therapy as first-line treatment for Helicobacter pylori infection.
- Author:
Mei-hua XU
1
;
Gui-ying ZHANG
;
Chang-juan LI
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Anti-Bacterial Agents; administration & dosage; economics; therapeutic use; Anti-Ulcer Agents; administration & dosage; economics; therapeutic use; Bismuth; administration & dosage; economics; therapeutic use; Cost-Benefit Analysis; Drug Therapy, Combination; economics; Female; Follow-Up Studies; Helicobacter Infections; drug therapy; Humans; Male; Middle Aged; Treatment Outcome
- From: Journal of Zhejiang University. Medical sciences 2011;40(3):327-331
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy of bismuth-based quadruple therapy as the first-line treatment for H.pylori infection.
METHODSA total of 136 patients with H.pylori related peptic ulcer or chronic gastritis were randomized into two groups: 67 patients in bismuth-based quadruple group received esomeprazole 20 mg, clarithromycin 0.5 g,amoxicillin 1.0 g,and bismuth potassium citrate 220 mg for 7 d; 69 patients in standard triple group received esomeprazole 20 mg, clarithromycin 0.5 g and amoxicillin 1.0 g for 7 d. Outcome of eradication therapy was assessed by (14)C-UBT. On ITT and PP analysis, calculating the cost-effectiveness ratio (C/E) and the incremental cost-effectiveness ratio (delta C/delta E).
RESULTOn ITT and PP analysis, the eradication rates of the quadruple therapy group were 82.09% and 88.71%, and those of the triple therapy group were 66.67% and 73.02% (P<0.05). The cost-effectiveness ratio of two groups was 4.15 and 4.82; The incremental cost-effectiveness ratio of quadruple therapy group was 1.02 as against triple therapy group.
CONCLUSIONCompared to the standard triple therapy regimen, the bismuth-containing quadruple therapy regimen has higher eradication rate and cost-effectiveness, which can be recommended as the fist-line treatment for H.pylori infection.